Informa Sells Pharma Intelligence Business for £1.9bn

Information services group Informa has sold its Pharma Intelligence business to private equity firm Warburg Pincus for £1.9bn. Abu Dhabi-based Mubadala Investment Company joined Warburg Pincus in the deal, which sees Informa retain a 15% stake in the business.

Pharma Intelligence offers specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance. The company provides insights on patient enrolment and demographics, trial progress, individual trial sites and investigators for more than 375,000 clinical trials across 180 countries. The acquisition includes Informa's full portfolio of specialist brands which includes the Citeline suite, Trialtrove, Sitetrove, Pharmaprojects and Citeline branded products, as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Skipta, and TrialScope.

Commenting on the deal, Warburg Pincus said it believes demand for the Pharma Intelligence services will increase, as the world becomes more data driven and focused on using predictive analytics to solve health issues. Stephen Carter (pictured), Group CEO, Informa, adds: 'We received significant interest in the Pharma Intelligence business. We are delighted to partner with Warburg Pincus and share their view on its future growth potential, hence, we welcomed an agreement that represented value today and growth and value tomorrow.'

In December, Informa announced the planned sale of its data and consultancy business Informa Intelligence, and later that month, found a buyer for its Asset Intelligence Business unit.

Web site: www.informa.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.